This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Policy

InOncology.com

Our Compounds

Our extensive oncology clinical trial programme has produced two approved drugs, as well as several other investigational compounds that are currently bring investigated across a broad range of tumour types. Find out more below. 

Download a PDF of our compounds
Filter by:
Focus Area
Development stage
Compound Target Focus area Development stage
  • Phase I
  • Phase II
  • Phase III
  • Approved

Afatinib
NCE po (GIOTRIF®)

Discover more
  • EGFR (ErbB1); HER2 (ErbB2); ErbB3; ErbB4
  • Non-small cell lung cancer first line epidermal growth factor mutation-positive
  1. 1
  2. 2
  3. 3
  4. A
  • Squamous histology non-small cell carcinoma
  1. 1
  2. 2
  3. 3
  4. A
  • Head and neck squamous cell carcinoma
  1. 1
  2. 2
  3. 3
  4. A
  • Urothelial carcinoma
  1. 1
  2. 2
  3. 3
  4. A

Nintedanib
NCE po (VARGATEF®)

Discover more
  • VEGFR; FGFR; PDGFR
  • Non-small cell lung cancer second line
  1. 1
  2. 2
  3. 3
  4. A
  • Malignant pleural mesothelioma
  1. 1
  2. 2
  3. 3
  4. A

BI 695502
Bevacizumab biosimilar candidate

  • VEGF
  • Non-squamous non-small cell lung cancer
  1. 1
  2. 2
  3. 3
  4. A
  • Metastatic colorectal cancer
  1. 1
  2. 2
  3. 3
  4. A

Xentuzumab
NBE iv

Discover more
  • IGF1; IGF2
  • Breast cancer (Phase I/II)
  1. 1
  2. 2
  3. 3
  4. A
  • Castration-resistant prostate cancer (Phase I/II)
  1. 1
  2. 2
  3. 3
  4. A
  • Solid tumours
  1. 1
  2. 2
  3. 3
  4. A
  • Non-small cell lung cancer
  1. 1
  2. 2
  3. 3
  4. A

BI 836858
NBE iv

Discover more
  • CD33
  • Acute myeloid leukaemia
  1. 1
  2. 2
  3. 3
  4. A
  • Myelodysplastic syndrome
  1. 1
  2. 2
  3. 3
  4. A

BI 836826
NBE iv

Discover more
  • CD37
  • Chronic lymphocytic leukaemia
  1. 1
  2. 2
  3. 3
  4. A
  • Diffuse large B-cell lymphoma (Ph I/II)
  1. 1
  2. 2
  3. 3
  4. A
  • Chronic lymphocytic leukaemia
  1. 1
  2. 2
  3. 3
  4. A
  • Non-Hodgkin lymphoma
  1. 1
  2. 2
  3. 3
  4. A

BI 836880
NBE iv

Discover more
  • VEGF; Ang-2
  • Solid tumours
  1. 1
  2. 2
  3. 3
  4. A

BI 1361849
mRNA-based ICV (CV9202)

Discover more
  • NY-ESO-1; MAGE C1; MAGE C2; TPBG; Survivin; MUC1
  • Non-small cell lung cancer
  1. 1
  2. 2
  3. 3
  4. A

BI 754091
NBE iv

Discover more
  • PD-1
  • Solid tumours
  1. 1
  2. 2
  3. 3
  4. A

BI 894999
NCE po

Discover more
  • BET
  • Solid tumours - non-Hodgkin lymphoma
  1. 1
  2. 2
  3. 3
  4. A

BI 754091 / BI 754111
NBE iv

  • PD-1/LAG3
  • Solid tumours
  1. 1
  2. 2
  3. 3
  4. A

BI 754091 / BI 891065
NCE po

  • PD-1/SMAC
  • Solid tumours
  1. 1
  2. 2
  3. 3
  4. A
Download a PDF of our compounds
Back to top

*Afatinib is approved in more than 70 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.

**Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.

This is an investigational compound and has not been approved. Its safety and efficacy have not been established.

 

Ang-2, angiopoietin-2; BET, bromodomain and extra terminal motif; CD, cluster of differentiation; EGFR, epidermal growth factor receptor; ErbB, epidermal growth factor receptor tyrosine kinase family receptor; FGFR, fibroblast growth factor receptor; HER2, human epidermal growth factor receptor 2; IGF, insulin-like growth factor; iv, intravenous; LAG3, lymphocyte activation gene 3 protein; MAGE, melanoma-associated antigen; mRNA-based ICV, messenger ribonucleic acid-based immunotherapeutic cancer vaccine; MUC1, mucin 1, cell surface associated; NBE, new biological entity; NCE, new chemical entity; NY-ESO-1, New York esophageal squamous cell carcinoma 1; PD-1, programmed cell death protein 1; po, orally; PDGFR, platelet-derived growth factor receptor; SMAC, second mitochondria-derived activator of caspase; TPBG, trophoblast glycoprotein; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.